FEB 28 '94 0i:2lPn SMITH RESERRCH TOWER 
P. 13/14 
Case histories, the results of treatment, laboratory and pathologic data, photographs 
and x-rays may be published for scientific purposes, but neither your child's or your 
identity will be disclosed and confidentiality will be maintained. The Food and Drug 
Administration (FDA), the Department of Health and Human Services (DHHS) and/or 
their designate(s), the company manufacturing the vector (the weakened virus that 
carries the DNA for gamma interferon), and appropriate personnel of Childrens 
Hospital Los Angeles may inspect the records relating to your (your child's) 
participation in the study. If the study plan or use of the information is to be changed, 
you will be so informed. 
VOLUNTARY PARTICIPATION 
This study program has been reviewed, and its consent form has been approved by 
the Committee on Clinical Investigations (also called the IRB-lnstitutional Review 
Board). The approval of this Committee does not alter the fact that the final decision 
to enter yourself (your child) in the study program is yours. Refusal to participate in 
this study will involve no loss of benefits or penalize your (your child's) care. You 
have the right to remove yourself (your child) from the study at any time. Your 
attending physician. Dr. will answer any questions you may 
have regarding the study. Subsequent medical care at the Childrens Hospital Los 
Angeles is in no way contingent upon participation in this study program. 
HOW TO OBTAIN INFORMATION 
Daytime Monday through Friday, 8 a.m. to 5 p.m., you may call (21 3) 669-2121 . You 
may leave a message with a secretary, and a doctor will return your call. Evening, 
nighttime, and weekends or holidays: You may call the hospital number (213) 660- 
2450 . and ask for the on-call doctor for the Hematology-Oncology Service. You may 
be asked to leave a message with the page operator, and the physician on-call will 
return your call as soon as possible. 
If you have questions regarding your(your child's) rights as a patient with regard to 
this study program, you can contact Ms. Gwenn Oki, Administrator of The Committee 
on Clinical Investigations(IRB) at (213) 669-2265. 
[ 120 ] 
Recombinant DNA Research, Volume l9 
